A phase I/II study of CR011-vcMMAE in subjects with unresectable stage III or stage IV melanoma.
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2015
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors CuraGen Corporation
- 07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2010 Results will be presented at ASCO 2010 (Abstract Control Number: 51525; Permanent Abstract ID: 8525), according to a Celldex Therapeutics media release.